Cd19 Cart Cell Therapy In A Pediatric Patient With Mda5 Dermatomyositis And Rapidly Progressive Interstitial Lung Disease Andre S Parısmun Oz by Andre´ S Parı´s-mun˜ Oz, Rosa M. Alcobendas-rueda, Cristina Verdu´-sa´ Nchez, ..., Gonzalo Ruiz-zurita, Miguel A. Ferna´ Ndez-garcı´a, ´rez-martı´nezantonio Pe 101016/JMEDJ2025100676 instant download after payment.

CONTEXT AND SIGNIFICANCE MDA5+ dermatomyositis with interstitial lung disease (MDA5+DM-RPILD) is arare autoimmune disease that lacks a well-defined treatment. Because B cells are key players in autoimmunity, CD19 CAR-T cell therapies have been proposed as a strategy to deeply deplete this cell population. Inthis report, researchers from Hospital Universitario La Paz describe the use of CD19 CAR-T cell therapy in apediatric patient with MDA5+DM-RPILD after a complex immunosuppressive regimen. For 11 months in animmunosuppressant-free context, the subject progressively exhibited motor and lung improvements andrestoration of the B cell compartment in the absence of autoimmune episodes. This work joins the list of autoimmune cases successfully treated with CAR-T cell therapies and demonstrates their efficacy and safetyeven in dire clinical conditions.SUMMARYBackground: Anti-melanoma differentiation-associated protein 5 dermatomyositis (MDA5+DM) is a potentially fatal subtype of dermatomyositis. The most severe cases are characterized by rapidly progressiveinterstitial lung disease (RPILD), the leading cause of death in these patients. There is currently no curativ